This Article Order Full text via Infotrieve Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mechtersheimer, G. Articles by Moller, P. Search for Related Content PubMed PubMed Citation Articles by Mechtersheimer, G. Articles by Moller, P.

American Journal of Pathology, Vol 137, 1215-1222, Copyright © 1990 by American Society for Investigative Pathology

REGULAR ARTICLES

Expression of aminopeptidase N (CD13) in mesenchymal tumors

G Mechtersheimer and P Moller
Institute of Pathology, Heidelberg University, Federal Republic of Germany.

For a long time, CD13 molecules have been considered to be restricted to myeloid cells and related neoplasms. Meanwhile, however, expression of CD13 has also been detected in some hepatocellular, gallbladder, renal, and lung carcinomas, and even in some fibrosarcomas and malignant melanomas. In this study, expression of CD13 antigen was immunohistochemically examined in non-neoplastic mesenchymal cells, along with 33 benign and 83 malignant mesenchymal tumors (MET) using CD13 monoclonal antibodies (MAb) My7, U71, WM-15, and MoU48. In non- neoplastic mesenchymal cells, expression of CD13 was restricted to perivascular fibrocytes/blasts, tissue histiocytes, osteoclasts, and to the perineurium of peripheral nerve trunks. Under neoplastic conditions, CD13 was detectable in some tumors of smooth muscle, fibrous, fibrohistiocytic, synovial, osteogenic, and peripheral nerve sheath origin, and even in some tumors of adipose tissue. Tumors of striated muscle origin, of autonomic ganglia, and of cartilage-forming tissues were CD13-negative throughout. Thus in most but not all tumors studied the pattern of expression of CD13 mirrors the situation found in their cells of origin. These findings enrich the data on expression of leukocyte differentiation antigens in extra-hematopoietic tissues. Expression of CD13, which meanwhile is known to be identical to aminopeptidase N, an important peptide-cleaving enzyme, in only some MET might reflect a special functional state of these neoplasms.

This article has been cited by other articles:

				J. E. Dennis, K. Esterly, A. Awadallah, C. R. Parrish, G. M. Poynter, and K. L. Goltry Clinical-Scale Expansion of a Mixed Population of Bone Marrow-Derived Stem and Progenitor Cells for Potential Use in Bone Tissue Regeneration Stem Cells, October 1, 2007; 25(10): 2575 - 2582. [Abstract] [Full Text] [PDF]

				R. Rangel, Y. Sun, L. Guzman-Rojas, M. G. Ozawa, J. Sun, R. J. Giordano, C. S. Van Pelt, P. T. Tinkey, R. R. Behringer, R. L. Sidman, et al. Impaired angiogenesis in aminopeptidase N-null mice PNAS, March 13, 2007; 104(11): 4588 - 4593. [Abstract] [Full Text] [PDF]

				C Rocken, J Licht, A Roessner, and S Carl-McGrath Canalicular immunostaining of aminopeptidase N (CD13) as a diagnostic marker for hepatocellular carcinoma J. Clin. Pathol., October 1, 2005; 58(10): 1069 - 1075. [Abstract] [Full Text] [PDF]

				Y. van Hensbergen, H. J. Broxterman, S. Rana, P. J. van Diest, M. C. A. Duyndam, K. Hoekman, H. M. Pinedo, and E. Boven Reduced Growth, Increased Vascular Area, and Reduced Response to Cisplatin in CD13-Overexpressing Human Ovarian Cancer Xenografts Clin. Cancer Res., February 1, 2004; 10(3): 1180 - 1191. [Abstract] [Full Text] [PDF]

				F. Curnis, G. Arrigoni, A. Sacchi, L. Fischetti, W. Arap, R. Pasqualini, and A. Corti Differential Binding of Drugs Containing the NGR Motif to CD13 Isoforms in Tumor Vessels, Epithelia, and Myeloid Cells Cancer Res., February 1, 2002; 62(3): 867 - 874. [Abstract] [Full Text] [PDF]